New England Biolabs, Inc.

Mehul Ganatra

Christopher H Taron

Siu-Hong Chan

G Brett Robb

Paul A Colussi

Paul Riggs

Iris Walker

Pei-Chung Hsieh

The present disclosure relates to compositions, kits, and methods of making RNA vaccines having an appropriate cap structure. Systems, apparatus, compositions, and/or methods may include and/or use, in some embodiments, non-naturally occurring single-chain RNA capping enzymes. In some embodiments, an RNA capping enzyme may include an FCE variant having (a) an amino acid sequence at least 90% identical to positions 1 to 878 of SEQ ID NO: 1, and/or (b) one or more substitutions relative to SEQ ID NO: 1 at a position selected from positions corresponding to positions 215, 337, 572, 648, and 833 (e.g., a position selected from positions corresponding to position 215, 337, and 572) of SEQ ID NO: 1.

FCE mRNA capping enzyme compositions, methods and kits

Methods and compositions are provided that relate to a composition that includes a modified maltose-binding protein (MBP) which when fused to a protein results in an increase in binding affinity for maltodextrin compared with the wild type MBP fused to the protein, the modified MBP maintaining enhanced solubility. The modification includes a mutation selected from the group consisting of: F68L, I318V, Q326R, V344M, and TTTTITITTTLGIEGRor consists of two or more mutations selected from the group consisting of: F68L, S146T, A313V, I318V, I318A, Q326R, V344M and TTTTITITTTLGIEGRmutants.

Solubilization and purification of a target protein fused to a mutant maltose-binding protein

Methods and compositions are provided for increasing at least one of: (i) binding affinity of a target protein for a maltodextrin substrate and/or (ii) solubility of a target protein. The methods and compositions relate to a modified maltose-binding protein.

Growing community of inventors

Gloucester, MA, United States of America

Mehul Ganatra